Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 80023
1. Mijajlović MD, Pavlović A, Brainin M, Heiss WD, Quinn TJ, Ihle-Hansen HB, Hermann DM, Assayag EB, Richard E, Thiel A, Kliper E, Shin YI, Kim YH, Choi S, Jung S, Lee YB, Sinanović O, Levine DA, Schlesinger I, Mead G, Milošević V, Leys D, Hagberg G, Ursin MH, Teuschl Y, Prokopenko S, Mozheyko E, Bezdenezhnykh A, Matz K, Aleksić V, Muresanu D, Korczyn AD, Bornstein NM: Post-stroke dementia - a comprehensive review. BMC Med; 2017 Jan 18;15(1):11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-stroke dementia - a comprehensive review.
  • : Post-stroke dementia (PSD) or post-stroke cognitive impairment (PSCI) may affect up to one third of stroke survivors.
  • We propose PSD as a label for any dementia following stroke in temporal relation.
  • A comprehensive evaluation should include assessment of pre-stroke cognition (e.g., using Informant Questionnaire for Cognitive Decline in the Elderly), mood (e.g., using Hospital Anxiety and Depression Scale), and functional consequences of cognitive impairments (e.g., using modified Rankin Scale).
  • Currently, no specific biomarkers have been proven to robustly discriminate vulnerable patients ('at risk brains') from those with better prognosis or to discriminate Alzheimer's disease dementia from PSD.
  • The role of computerized tomography is limited to demonstrating type and location of the underlying primary lesion and indicating atrophy and severe white matter changes.
  • Magnetic resonance imaging is the key neuroimaging modality and has high sensitivity and specificity for detecting pathological changes, including small vessel disease.
  • Quantitative imaging of cerebral blood flow and metabolism by positron emission tomography can differentiate between vascular dementia and degenerative dementia and show the interaction between vascular and metabolic changes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28095900.001).
  • [ISSN] 1741-7015
  • [Journal-full-title] BMC medicine
  • [ISO-abbreviation] BMC Med
  • [Language] eng
  • [Publication-type] Review; Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Biomarkers / Cognitive impairment / Definitions and classification / Dementia / Diagnosis / Interventions / Neuroimaging / Stroke
  •  go-up   go-down


2. O'Donnell CA, Browne S, Pierce M, McConnachie A, Deckers K, van Boxtel MP, Manera V, Köhler S, Redmond M, Verhey FR, van den Akker M, Power K, Irving K, In-MINDD Team: Reducing dementia risk by targeting modifiable risk factors in mid-life: study protocol for the Innovative Midlife Intervention for Dementia Deterrence (In-MINDD) randomised controlled feasibility trial. Pilot Feasibility Stud; 2015;1:40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reducing dementia risk by targeting modifiable risk factors in mid-life: study protocol for the Innovative Midlife Intervention for Dementia Deterrence (In-MINDD) randomised controlled feasibility trial.
  • BACKGROUND: Dementia prevalence is increasing as populations live longer, with no cure and the costs of caring exceeding many other conditions.
  • There is increasing evidence for modifiable risk factors which, if addressed in mid-life, can reduce the risk of developing dementia in later life.
  • This study aims to assess the acceptability and feasibility and impact of giving those in mid-life, aged between 40 and 60 years, an individualised dementia risk modification score and profile and access to personalised on-line health information and goal setting in order to support the behaviour change required to reduce such dementia risk.
  • A secondary aim is to understand participants' and practitioners' views of dementia prevention and explore the acceptability and integration of the Innovative Midlife Intervention for Dementia Deterrence (In-MINDD) intervention into daily life and routine practice.
  • METHODS/DESIGN: In-MINDD is a multi-centre, primary care-based, single-blinded randomised controlled feasibility trial currently being conducted in four European countries (France, Ireland, the Netherlands and the UK).
  • Inclusion criteria will include age between 40 and 60 years; at least one modifiable risk factor for dementia risk (including diabetes, hypertension, obesity, renal dysfunction, current smoker, raised cholesterol, coronary heart disease, current or previous history of depression, self-reported sedentary lifestyle, and self-reported low cognitive activity) access to the Internet.
  • Primary outcome measure will be a change in dementia risk modification score over the timescale of the trial (6 months).
  • A qualitative process evaluation will interview a sample of participants and practitioners about their views on the acceptability and feasibility of the trial and the links between modifiable risk factors and dementia prevention.
  • DISCUSSION: This study will explore the feasibility and acceptability of a risk profiler and on-line support environment to help individuals in mid-life assess their risk of developing dementia in later life and to take steps to alleviate that risk by tackling health-related behaviour change.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27965818.001).
  • [Journal-full-title] Pilot and feasibility studies
  • [ISO-abbreviation] Pilot Feasibility Stud
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Dementia / Internet / Modifiable risk factors / Primary care / Primary prevention
  •  go-up   go-down


3. Wang R, Chen Z, Fu Y, Wei X, Liao J, Liu X, He B, Xu Y, Zou J, Yang X, Weng R, Tan S, McElroy C, Jin K, Wang Q: Plasma Cystatin C and High-Density Lipoprotein Are Important Biomarkers of Alzheimer's Disease and Vascular Dementia: A Cross-Sectional Study. Front Aging Neurosci; 2017;9:26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma Cystatin C and High-Density Lipoprotein Are Important Biomarkers of Alzheimer's Disease and Vascular Dementia: A Cross-Sectional Study.
  • <b>Objectives</b>: Cystatin C (Cys C) and high-density lipoprotein (HDL) play critical roles in neurodegenerative diseases, such as dementia, Alzheimer's disease (AD) and vascular dementia (VaD).
  • However, whether they can be used as reliable biomarkers to distinguish patients with dementia from healthy subjects and to determine disease severity remain largely unknown.
  • <b>Methods</b>: We conducted a cross-sectional study to determine plasma Cys C and HDL levels of 88 patients with dementia (43 AD patients, 45 VaD patients) and 45 healthy age-matched controls.
  • The severity of dementia was determined based on the Schwab and England Activities of Daily Living (ADL) Scale, the Mini-mental State Examination (MMSE), the Global Deterioration Scale (GDS), the Lawton Instrumental ADL (IADL) Scale, and the Hachinski Ischemia Scale (Hachinski).
  • Receiver operating characteristic (ROC) curves were calculated to determine the diagnostic accuracy of Cys C and HDL levels in distinguishing patients with dementia from healthy subjects.
  • <b>Conclusions</b>: Our findings suggest that the inflammatory mediators Cys C and HDL may play important roles in the pathogenesis of dementia, and plasma Cys C and HDL levels may be useful screening tools for differentiating AD/VaD patients from healthy subjects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Front Aging Neurosci. 2015 Oct 27;7:203 [26578949.001]
  • [Cites] Curr Alzheimer Res. 2011 Mar;8(2):187-96 [21222606.001]
  • [Cites] J Alzheimers Dis. 2014;40(2):399-408 [24448787.001]
  • [Cites] Curr Alzheimer Res. 2014 May;11(4):340-8 [24720893.001]
  • [Cites] PLoS One. 2013;8(1):e55328 [23383156.001]
  • [Cites] Prog Neurobiol. 2013 Nov;110:2-28 [24036231.001]
  • [Cites] Neurology. 2008 Sep 30;71(14):1072-9 [18824671.001]
  • [Cites] Front Aging Neurosci. 2014 Jun 12;6:121 [24971061.001]
  • [Cites] Neurology. 1993 Feb;43(2):250-60 [8094895.001]
  • [Cites] Front Cell Neurosci. 2012 Dec 12;6:58 [23248582.001]
  • [Cites] Brain. 2011 Jan;134(Pt 1):258-77 [21186265.001]
  • [Cites] Front Cell Neurosci. 2014 Aug 14;8:231 [25177270.001]
  • [Cites] J Alzheimers Dis. 2010;21(2):471-8 [20555147.001]
  • [Cites] Cell Metab. 2014 Apr 1;19(4):574-91 [24508505.001]
  • [Cites] Neurology. 2014 Jul 1;83(1):40-7 [24907234.001]
  • [Cites] Front Mol Neurosci. 2012 Jul 06;5:79 [22783166.001]
  • [Cites] Front Aging Neurosci. 2016 Jul 28;8:179 [27516739.001]
  • [Cites] Neurobiol Aging. 2013 May;34(5):1389-96 [23273574.001]
  • [Cites] Front Aging Neurosci. 2010 Jul 15;2:null [20725527.001]
  • [Cites] J Alzheimers Dis. 2010;22(3):985-91 [20858959.001]
  • [Cites] J Neurochem. 2012 Aug;122(4):752-63 [22679891.001]
  • [Cites] Neurobiol Dis. 2014 Dec;72 Pt A:22-36 [25131449.001]
  • [Cites] Aging Dis. 2013 Mar 07;4(2):57-64 [23696950.001]
  • [Cites] Mol Neurodegener. 2015 Dec 01;10:64 [26627638.001]
  • [Cites] Mol Neurobiol. 2014 Apr;49(2):1043-54 [24203677.001]
  • [Cites] J Alzheimers Dis. 2009;16(2):389-97 [19221428.001]
  • [Cites] Front Cell Neurosci. 2015 Jul 06;9:247 [26217177.001]
  • [Cites] Front Biosci (Schol Ed). 2011 Jan 01;3:541-54 [21196395.001]
  • [Cites] Aging Dis. 2015 Oct 01;6(5):322-30 [26425387.001]
  • [Cites] PLoS One. 2013 Apr 23;8(4):e62354 [23626805.001]
  • [Cites] Neurology. 2014 Nov 11;83(20):1812-8 [25305153.001]
  • [Cites] Autophagy. 2011 Jul;7(7):788-9 [21464620.001]
  • [Cites] Sci Rep. 2016 Aug 04;6:30741 [27489174.001]
  • [Cites] Neurobiol Dis. 2005 Feb;18(1):152-65 [15649706.001]
  • [Cites] Am J Pathol. 2010 Nov;177(5):2256-67 [20889561.001]
  • [Cites] Front Aging Neurosci. 2013 Sep 09;5:50 [24058343.001]
  • [Cites] Nat Genet. 2007 Dec;39(12):1440-2 [18026100.001]
  • [Cites] Neurobiol Aging. 2011 Aug;32(8):1435-42 [19773092.001]
  • [Cites] Brain. 2014 Dec;137(Pt 12):3300-18 [25270989.001]
  • [Cites] Prog Neurobiol. 2015 Jul 21;:null [26209472.001]
  • [Cites] Neurology. 1984 Jul;34(7):939-44 [6610841.001]
  • (PMID = 28223934.001).
  • [Journal-full-title] Frontiers in aging neuroscience
  • [ISO-abbreviation] Front Aging Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Alzheimer’s disease / cystatin C / dementia / high-density lipoprotein / vascular dementia
  •  go-up   go-down


Advertisement
4. Yu H, Chen T, Zhou L, Tang J: Effect of Selective 5-HT6R Agonist on Expression of 5-HT Receptor and Neurotransmitter in Vascular Dementia Rats. Med Sci Monit; 2017 Feb 15;23:818-825
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Selective 5-HT6R Agonist on Expression of 5-HT Receptor and Neurotransmitter in Vascular Dementia Rats.
  • However, whether 5-HT6R is involved in the development of vascular dementia (VD) remains unclear.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28196966.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Hewer W, Thomas C: [Treatment with psychotropic agents in patients with dementia and delirium : Gap between guideline recommendations and treatment practice]. Z Gerontol Geriatr; 2017 Feb;50(2):106-114
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment with psychotropic agents in patients with dementia and delirium : Gap between guideline recommendations and treatment practice].
  • [Transliterated title] Psychopharmakotherapie bei Demenz und Delir : Im Spannungsfeld zwischen Leitlinienempfehlungen und Versorgungspraxis.
  • BACKGROUND AND OBJECTIVES: Psychiatric symptoms in dementia and delirium are associated with a substantially reduced quality of life of patients and their families and often challenging for professionals.
  • MATERIAL AND METHODS: Narrative review with special reference to the German dementia guideline from 2016 and recently published practice guidelines for delirium in old age in German and English language.
  • RESULTS: The indications for use of psychotropic agents, especially antipsychotics, are defined narrowly in the German dementia guideline.
  • Comparable to the German dementia guideline they recommend general medical interventions and nonpharmacological treatment as first line measures and the use of psychotropic agents only under certain conditions.
  • CONCLUSION: The guidelines discussed here advocate well-founded a cautious prescription of psychotropic agents in patients with dementia and delirium.
  • Most notably, however, epidemiological data disclose an unacceptable rate of hazardous overtreatment with psychotropic agents, especially in long-term care of persons with dementia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28124100.001).
  • [ISSN] 1435-1269
  • [Journal-full-title] Zeitschrift fur Gerontologie und Geriatrie
  • [ISO-abbreviation] Z Gerontol Geriatr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Administration and dosage / Drug monitoring / Evidence-based medicine / Nonpharmacological treatment
  •  go-up   go-down


6. Xu J, Wang J, Wimo A, Fratiglioni L, Qiu C: The economic burden of dementia in China, 1990-2030: implications for health policy. Bull World Health Organ; 2017 Jan 01;95(1):18-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The economic burden of dementia in China, 1990-2030: implications for health policy.
  • OBJECTIVE: To quantify and predict the economic burden of dementia in China for the periods 1990-2010 and 2020-2030, respectively, and discuss the potential implications for national public health policy.
  • METHODS: Using a societal, prevalence-based, gross cost-of-illness approach and data from multiple sources, we estimated or predicted total annual economic costs of dementia in China.
  • FINDINGS: The estimated total annual costs of dementia in China increased from 0.9 billion United States dollars (US$) in 1990 to US$ 47.2 billion in 2010 and were predicted to reach US$ 69.0 billion in 2020 and US$ 114.2 billion in 2030.
  • In China, population ageing and the increasing prevalence of dementia were the main drivers for the increasing predicted costs of dementia between 2010 and 2020, and population ageing was the major factor contributing to the growth of dementia costs between 2020 and 2030.
  • CONCLUSION: In China, demographic and epidemiological transitions have driven the growth observed in the economic costs of dementia since the 1990s.
  • If the future costs of dementia are to be reduced, China needs a nationwide dementia action plan to develop an integrated health and social care system and to promote primary and secondary prevention.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28053361.001).
  • [ISSN] 1564-0604
  • [Journal-full-title] Bulletin of the World Health Organization
  • [ISO-abbreviation] Bull. World Health Organ.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


7. Fan YC, Hsu JL, Tung HY, Chou CC, Bai CH: Increased dementia risk predominantly in diabetes mellitus rather than in hypertension or hyperlipidemia: a population-based cohort study. Alzheimers Res Ther; 2017 Feb 06;9(1):7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased dementia risk predominantly in diabetes mellitus rather than in hypertension or hyperlipidemia: a population-based cohort study.
  • BACKGROUND: The pathophysiology of insulin resistance-induced hypertension and hyperlipidemia might entail differences in dementia risk in cases with hypertension and hyperlipidemia without prior diabetes mellitus (DM).
  • This study investigated whether incident hypertension, incident hyperlipidemia, or both, increased the dementia risk in patients with and without DM.
  • We enrolled 10,316 patients with a new diagnosis of DM between 2000 and 2002 in the DM cohort.
  • The dementia risk was higher in the DM cohort than in the non-DM cohort (adjusted hazard ratio (HR) = 1.47, 95% confidence interval (CI) = 1.30-1.67, p < 0.001).
  • In the DM cohort, the dementia risk in patients with both hypertension and hyperlipidemia did not significantly increase compared with that in those without hypertension and hyperlipidemia (p = 0.529).
  • In the non-DM cohort, patients with both hypertension and hyperlipidemia had a higher dementia risk (adjusted HR = 1.33, 95% CI = 1.09-1.63, p = 0.006).
  • However, the dementia risk did not increase significantly in patients with only hyperlipidemia (p = 0.187).
  • CONCLUSIONS: The development of hypertension, hyperlipidemia, or both, following a diagnosis of incident diabetes is secondary to diabetes onset and likely mediated through insulin resistance associated with diabetes, which does not further accentuate dementia risk.
  • DM itself (i.e., the systemic influence of hyperglycemia) might be the main driver of increased dementia risk.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28162091.001).
  • [ISSN] 1758-9193
  • [Journal-full-title] Alzheimer's research & therapy
  • [ISO-abbreviation] Alzheimers Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Dementia / Diabetes mellitus / Hyperlipidemia / Hypertension / National Health Insurance Research Database
  •  go-up   go-down


8. Smith D, Lovell J, Weller C, Kennedy B, Winbolt M, Young C, Ibrahim J: A systematic review of medication non-adherence in persons with dementia or cognitive impairment. PLoS One; 2017;12(2):e0170651
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic review of medication non-adherence in persons with dementia or cognitive impairment.
  • BACKGROUND: Adherence to medication is vital for disease management while simultaneously reducing healthcare expenditure.
  • METHODS: A seven database systematic search of studies published between 1 January 1949-31 December 2015 examining medication non-adherence in community dwelling persons with CI or dementia was conducted.
  • Articles reporting medication non-adherence in people with CI or dementia in the community, with or without caregiver supports were eligible for inclusion.
  • Papers reporting adherence to treatments in cognitively intact populations, populations from hospital or institutional settings, for non-prescribed medication or those describing dementia as a factor predicting medication non-adherence were excluded.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Psychol Aging. 1992 Jun;7(2):252-6 [1610514.001]
  • [Cites] Telemed J E Health. 2009 Oct;15(8):770-6 [19780692.001]
  • [Cites] J Gerontol B Psychol Sci Soc Sci. 2006 Mar;61(2):P102-7 [16497953.001]
  • [Cites] Circulation. 2009 Jun 16;119(23):3028-35 [19528344.001]
  • [Cites] Scand J Prim Health Care. 1989 Oct;7(3):179-80 [2587874.001]
  • [Cites] Eur J Cardiovasc Nurs. 2003 Sep;2(3):219-28 [14622630.001]
  • [Cites] Heart Lung. 2012 Nov-Dec;41(6):572-82 [22784869.001]
  • [Cites] Ann Behav Med. 2003 Aug;26(1):1-7 [12867348.001]
  • [Cites] Drugs Aging. 2008;25(12):1033-47 [19021302.001]
  • [Cites] BMC Med. 2014 Oct 31;12:192 [25358236.001]
  • [Cites] Int J Geriatr Psychiatry. 2007 Jan;22(1):55-60 [17006873.001]
  • [Cites] J Gerontol Nurs. 1994 Jul;20(7):41-7 [8046218.001]
  • [Cites] Health Psychol. 2010 Jan;29(1):50-5 [20063935.001]
  • [Cites] J Clin Epidemiol. 2001 Dec;54 Suppl 1:S57-60 [11750211.001]
  • [Cites] BMJ. 2009 Jul 21;339:b2700 [19622552.001]
  • [Cites] Curr Clin Pharmacol. 2015;10(3):213-21 [26265487.001]
  • [Cites] Am J Alzheimers Dis Other Demen. 2012 Jun;27(4):238-42 [22739031.001]
  • [Cites] Aging Clin Exp Res. 2012 Dec;24(6):718-21 [22732397.001]
  • [Cites] Ann Pharmacother. 2009 Feb;43(2):185-93 [19193586.001]
  • [Cites] Cancer Prev Res (Phila). 2014 Jan;7(1):161-8 [24253314.001]
  • [Cites] Am J Geriatr Pharmacother. 2012 Jun;10(3):165-77 [22657941.001]
  • [Cites] J Health Serv Res Policy. 2005 Jul;10 Suppl 1:21-34 [16053581.001]
  • [Cites] Neuropsychology. 2015 Nov;29(6):919-25 [25730729.001]
  • [Cites] Drugs Aging. 2004;21(12):793-811 [15382959.001]
  • [Cites] Am J Geriatr Pharmacother. 2008 Dec;6(5):255-63 [19161928.001]
  • [Cites] Am J Health Promot. 2010 Nov-Dec;25(2):126-33 [21039294.001]
  • [Cites] Appl Neuropsychol. 2002;9(3):187-91 [12584085.001]
  • [Cites] Int J Geriatr Psychiatry. 1997 Sep;12(9):920-5 [9309470.001]
  • [Cites] PLoS One. 2015 Dec 16;10(12):e0145076 [26674526.001]
  • [Cites] J Am Geriatr Soc. 1996 Jul;44(7):828-31 [8675933.001]
  • [Cites] J Nurs Scholarsh. 2003;35(3):207 [14562485.001]
  • [Cites] J Gerontol Soc Work. 2006;47(3-4):31-46 [17062521.001]
  • [Cites] J Gen Intern Med. 2005 Jul;20(7):572-7 [16050849.001]
  • [Cites] Am J Alzheimers Dis Other Demen. 2007 Feb-Mar;22(1):20-6 [17533998.001]
  • [Cites] Eur J Heart Fail. 2010 May;12(5):508-15 [20354031.001]
  • [Cites] Int J Geriatr Psychiatry. 2012 Dec;27(12):1275-82 [22337284.001]
  • [Cites] J Clin Pharm Ther. 2001 Oct;26(5):331-42 [11679023.001]
  • [Cites] Cochrane Database Syst Rev. 2014 Nov 20;(11):CD000011 [25412402.001]
  • [Cites] J Psychiatr Pract. 2009 Jan;15(1):34-44 [19182563.001]
  • [Cites] Clin Infect Dis. 2005 Sep 15;41(6):875-82 [16107989.001]
  • [Cites] Eur J Clin Pharmacol. 2001 Oct;57(8):589-94 [11758637.001]
  • [Cites] AIDS Behav. 2011 Nov;15(8):1888-94 [21437726.001]
  • (PMID = 28166234.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Guo K, Yin G, Zi XH, Zhu HX, Pan Q: Effect of selective serotonin reuptake inhibitors on expression of 5-HT1AR and neurotransmitters in rats with vascular dementia. Genet Mol Res; 2016 Dec 02;15(4)
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of selective serotonin reuptake inhibitors on expression of 5-HT1AR and neurotransmitters in rats with vascular dementia.
  • To investigate the function of SSRIs in vascular dementia (VD), we established a rat model of VD, and observed the effect of SSRIs on the expression of 5-HT1AR mRNA and neurotransmitters.
  • HPLC was used to determine the levels of dopamine (DA), 5-HT, and norepinephrine (NE).
  • This was accompanied by reductions in DA, 5-HT, and NE levels in hippocampal tissues, as well as reduced cortical 5-HT and decreased 5-HT1AR mRNA expression (P < 0.05).
  • [MeSH-major] Dementia, Vascular / drug therapy. Dopamine / metabolism. Norepinephrine / metabolism. Receptor, Serotonin, 5-HT1A / genetics. Serotonin / metabolism. Serotonin Uptake Inhibitors / administration & dosage
  • [MeSH-minor] Animals. Citalopram / administration & dosage. Citalopram / pharmacology. Disease Models, Animal. Gene Expression Regulation / drug effects. Hippocampus / drug effects. Hippocampus / metabolism. Humans. Injections, Intraperitoneal. Male. Neurons / drug effects. Neurons / metabolism. Random Allocation. Rats. Rats, Sprague-Dawley. Treatment Outcome

  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. DOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27966748.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Serotonin Uptake Inhibitors; 0DHU5B8D6V / Citalopram; 112692-38-3 / Receptor, Serotonin, 5-HT1A; 333DO1RDJY / Serotonin; VTD58H1Z2X / Dopamine; X4W3ENH1CV / Norepinephrine
  •  go-up   go-down


10. Some antipsychotic drugs prescribed for dementia increase likelihood of death. Nurs Stand; 2012 Apr 11;26(32):14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Some antipsychotic drugs prescribed for dementia increase likelihood of death.
  • : People over the age of 65 who take certain antipsychotic drugs for dementia are at an increased risk of death, suggests the largest study ever undertaken among nursing home residents in the United States.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28055339.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement